REM2
COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED
03/07/2026
Back to search
Official data from USPTO
VIRTUS
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
VIRTUS
ST13
US500000086587871Class
5, 35, 42
Filing
86587871
Registration
5111954
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
44
Latest update
03/08/2026
Trademark type
Word
Nice classes
5, 35, 42
Filing date
04/06/2015
Registration date
01/03/2017
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
09/08/2023
Last transaction
03/08/2026
Responsible office
United States Patent and Trademark Office
Status code
702
Official register
Principal Register
First use anywhere
10/01/2011
First use in commerce
10/01/2011
Drawing code
4
Owner type
16
Owner location
Newtown, PA, US
Examiner
WHEATLEY, TRAVIS DWIGHT
Law office
M80
Current location
TMO LAW OFFICE 117
Holders and representatives
Holders
Virtus Pharmaceuticals, LLC
Virtus Pharmaceuticals, LLC
Representatives
Laurence Tauber Cohen Tauber Speivack & Wgner P.C.
Technical classification
Nice Classes
Class 5Class 35Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceuticalsprescription and over-the-counter drugs for the treatment of illnessdisease or deficienciesbacterial infectionstreatment symptoms of seasonalperennial and chronic allergies and the treatment of skin hives and itching associated with skin reactionsType 2 diabetes mellitusTreatment and prevention of osteoporosis in postmenopausal womentreatment to increase bone mass in men with osteoporosistreatment of glucocorticoid induced osteoporosisTreatment of Paget's Disease of boneTreatment for the relief of discomfort associated with acute or painful musculoskeletal conditionsTreatment and management of moderate to moderately-severe pain in adultsTreatment of hypertensionTreatment of diabetic nephropathyTreatment of dermatitis herpetiformis and leprosyTreatment of chronic inflammatory skin disease marked by blistersTreatment of acid indigestionTreatment of upset stomachManagement and support for patients requiring increased folate levelsSupplementation in support of bone healthSupplementation in support of prenatal healthincludingwithout limitationincreased folic acidManagement and support of absorption of calcium and/or functioning of calcium in the bodyTreatment of Vitamin D deficiencySupplementation in support of postnatal healthTreatment and prevention of lack of vitaminsminerals and/or fatty acids during pregnancyTreatment and temporary relief of coughnasal congestionloosening of phlegm and thin bronchial secretionsTreatment and prevention of prenatal and postnatal folate deficiencyTreatment of elevated or high levels of uric acid and prevention and treatment of metabolic problems caused by kidney diseaseprevention of endometrial hyperplasia in nonhysterectomized postmenopausal women who are receiving conjugated estrogens tabletshormone replacement therapyPostnatal supplementation and improvement of nutritional states of women prior to conceptionprevention of acidosisstomach or bowel problemspeptic ulcers and irritable bowel syndromeTreatment for excessive saliva productionirritable colon and bladder dysfunctionTreatment of symptoms associated with disorders of gastrointestinal tractbladder spasmspeptic ulcer diseasediverticulitisirritable bowel syndromecystitis and pancreatitisPrevention and treatment of low blood levels of potassiumPrevention of Fetal Neural Tube Defects when pregnantTreatment of inadequate folic acidfolate deficiencyanemia from inadequate folic acidTreatment of Hyperhomocysteinemia
Class 35
Distributorship services in the field of prescription and over-the-counter drugs; marketing of prescription and over-the-counter drugs
Class 42
Development of pharmaceutical products
Publications
History of USPTO decisions and trademark events.
44 publications found
NA85
NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
09/08/2023
C15A
REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
09/08/2023
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
09/08/2023
E815
TEAS SECTION 8 & 15 RECEIVED
03/10/2023
REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
01/03/2022
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
01/11/2017
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
01/11/2017
R.PR
REGISTERED-PRINCIPAL REGISTER
01/03/2017
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
10/18/2016
PUBO
PUBLISHED FOR OPPOSITION
10/18/2016
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
09/28/2016
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
09/14/2016
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
09/01/2016
XAEC
EXAMINER'S AMENDMENT ENTERED
08/31/2016
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
08/31/2016
GNEA
EXAMINERS AMENDMENT E-MAILED
08/31/2016
CNEA
EXAMINERS AMENDMENT -WRITTEN
08/31/2016
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
08/15/2016
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
08/15/2016
ALIE
ASSIGNED TO LIE
08/13/2016
NREV
NOTICE OF REVIVAL - E-MAILED
08/05/2016
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
08/04/2016
PETG
PETITION TO REVIVE-GRANTED
08/04/2016
PROA
TEAS PETITION TO REVIVE RECEIVED
08/04/2016
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
07/18/2016
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
07/18/2016
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
02/03/2016
GNRT
NON-FINAL ACTION E-MAILED
02/03/2016
CNRT
NON-FINAL ACTION WRITTEN
02/03/2016
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
01/20/2016
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
01/20/2016
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
01/20/2016
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
07/21/2015
GNRT
NON-FINAL ACTION E-MAILED
07/21/2015
CNRT
NON-FINAL ACTION WRITTEN
07/21/2015
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
07/20/2015
GNRT
NON-FINAL ACTION E-MAILED
07/20/2015
CNRT
NON-FINAL ACTION WRITTEN
07/20/2015
DOCK
ASSIGNED TO EXAMINER
07/14/2015
TAEA
TEAS AMENDMENT ENTERED BEFORE ATTORNEY ASSIGNED
04/30/2015
PARI
TEAS VOLUNTARY AMENDMENT RECEIVED
04/30/2015
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
04/14/2015
NWAP
NEW APPLICATION ENTERED
04/09/2015
Continuous trademark protection
Get notified about every new filing that threatens VIRTUS or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.